Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human, Randomised, Double Blind, Placebo Controlled, Single and Multiple Ascending Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AJM347 in Healthy Male Caucasian and Japanese Subjects in the Fasted and Fed State

NCT03133468 is registered in ClinicalTrials.gov with EA Pharma Co., Ltd. as lead sponsor.

NCT NCT03133468
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03133468 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human, Randomised, Double Blind, Placebo Controlled, Single and Multiple Ascending Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AJM347 in Healthy Male Caucasian and Japanese Subjects in the Fasted and Fed State
Lead sponsor
EA Pharma Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
July 25, 2017
Completion date
July 6, 2018
Enrollment
200 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy participants